ABSTRACT. In an effort to develop more effective therapy for neonatal group B streptococcal infections, penicillin G and human immune serum globulin (ISG), alone and in combination, were evaluated for their therapeutic efficacy against experimental group B streptococcal bacteremia and meningitis in newborn rats. Infected rats received either penicillin G (200 mg/kg/day), ISG (2 g/kg) or penicillin G (200 mg/kg/day) + varying doses of ISG (0.25 to 2 g/kg).
humans and in experimental animals (4) (5) (6) (7) (8) . Recently, with the introduction of human immunoglobulin prepared for intravenous use (9) (10) (11) (12) , immunotherapy in conjunction with antimicrobial therapy has been suggested for the treatment of neonatal GBS infections.
The purpose of the present study was to evaluate the in vivo efficacy of human immunoglobulin alone and in combination with penicillin G in the treatment of experimental type 111 GBS bacteremia and meningitis. As shown previously (13) , a human immunoglobulin prepared by pH 4 treatment was more active in vitro and in vivo against a type 111 GBS strain than a reduced and alkylated preparation, and therefore the former was used for this study.
MATERIALS AND METHODS

Organism.
A type 111 GBS strain (K79) isolated from the CSF of a newborn infant with meningitis was used in this study. This strain was sensitive to penicillin G with the minimal inhibitory and minimal bactericidal concentrations of 0.06 and 0.06 pg/ml ( 14) .
ISG. A lyophilized preparation of human ISG (lot 2850) was obtained from Cutter Laboratories, Berkeley, CA. It is free of mercury-containing thimerosol preservative and prepared by treatment of Cohn fraction I1 with pH 4. When reconstituted in 10 ml sterile water, the solution contains 10% protein, of which at least 90% is IgG. The content of type 111 GBS antibody of human IgG class was 8.4 pg/ml as measured by ELISA (15) .
In vivo studies. Outbred, pathogen-free, Sprague-Dawley pregnant rats with timed conception were purchased from Charles River Breeding Laboratories, Wilmington, MA and gave birth in our vivarium 5 to 7 days after arrival. The methods to induce GBS bacteremia and meningitis in 5-day-old rats and to monitor the responses of such infections to treatment with antibiotics in terms of bacterial clearance in blood and CSF have been described previously (14, 16, 17) . Since the GBS was recognized as a major cause of serious A total of 122 animals from 10 litters was used. At 5 days of neonatal infection, penicillin G has been the mainstay of therapy age, all members of each litter were inoculated subcutaneously for these infections. However, despite consistent sensitivity of with 1 x lo5 CFU of strain K79. Eighteen hours after inoculation GBS to ~enicillin, the clinical response to appropriate therapy is and daily thereafter for 4 days, 0.1 ml blood and 0.01 mi CSF often poor. For this reason, several investigators have examined we, obtained for quantitative cultures. Immediately after the the potential use of other therapeutic modalities (e.g. leukocytes, first blood and CSF specimens were obtained, each litter was immunoglobulins) (1-3).
randomly divided into six treatment groups: group 1, penicillin 2 h within the therapeutic range (14) . Therapeutic efficacy was
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KIM determined by comparing rates of bacterial clearance from blood and CSF as well as mortality rates among the six groups. All surviving animals had one blood and CSF sample drawn at 1-2 h after subcutaneous administration of penicillin G on therapy day 3 to determine bactericidal titers. Bactericidal titers were determined by a microtiter technique (14, 16) with a serial 2-fold dilution of serum or CSF in Mueller-Hinton broth and an inoculum of strain K79 of approximately 5 x lo5 CFU/ml. The bactericidal titers in serum or CSF were defined as the highest dilution of serum or CSF that results in >99.9% killing.
Opsonophagocytic assays. Serum samples were also assayed for opsonic activity by a microtiter plate modification of the method of Hirsch and Strauss (18) . Neutrophils were isolated from Sprague-Dawley adult rats by dextran sedimentation followed by Ficoll-Hypaque density centrifugation (I 3). PMNs were washed and then adjusted to a concentration of 5 x 106/ml. This PMN preparation was contaminated with erythrocytes but consistently yielded PMNs >90% of the leukocytes. Neutrophils (approximately 2 x lo5 PMNs/40 p1) were added to roundbottom microtiter wells (Nunc, Roskilde, Denmark) along with 10 1 1 washed logarithmic-phase strain K79 (approximately 2 x 1 O5 CFU), 10 p1 pooled newborn rat serum (screened for absence of type I11 GBS antibody by ELISA) as a source of complement and 40 p1 serum that had been incubated at 37" C for 1 h in the presence of penicillinase (10,000 U/ml, Difco Laboratories, Detroit, MI) to inactivate any killing effect due to penicillin. Minimal essential medium with Earle's balanced salt solution (Gibco Laboratories, Santa Clara, CA) was used in washing and resuspension of PMNs and bacteria.
A final mixture contained a ratio of PMNs to bacteria of approximately 1 : 1. The microtiter plates were incubated at 37" C with constant shaking (American Rotator V, American Dade, Miami, FL). Aliquots (10 p1) were taken from each well at 0 and 1 h, serially diluted 10-fold in sterile distilled water, and plated on blood agar for determination of surviving CFUs. Results were expressed as the percentage of bacteria killed: 100-(CFU at 1 h/ CFU at 0 h x 100). Statistical methods. The xZ test (with the Yates' correction for small samples) was used to compare the incidence of bacteremia and mortality and the Student's t test to compare the magnitude of bacteremia and opsonic activity among groups of animals (19) . P values of 4 0.05 were considered significant.
RESULTS
In vivo eficacy. GBS bacteremia was present in all 122 (100%)
animals and meningitis (positive CSF culture) developed in 53 (43%) animals 18 h after infection and just before therapy (Table  I) . At this time, the prevalence of meningitis and the bacterial counts in blood and CSF did not differ significantly in the animals assigned to the various treatment groups (Table 1) . Table 1 compares the overall mortality and bacterial clearance from blood and CSF among the six treatment groups. All animals receiving ISG alone died within 2 days of therapy. Otherwise, the mortality rates among the remaining five groups were not significantly different.
The bacterial clearance from blood of the six treatment groups was compared by determining bacterial counts of animals with positive blood cultures at 1, 2, and 3 days of completed therapy (Table 1) . In every group, the number of animals available for ISG I (g/kg) (n = 9)
Penicillin G + Bactericidal and opsonic activity. Bactericidal titers in serum and CSF obtained 1-2 h after subcutaneous administration of penicillin G on therapy day 3 were >5 12 and 5 14 + 5 (geometric mean + SEM of reciprocals of bactericidal titers), respectively, and these values did not differ significantly from those of animals that received penicillin G + varying doses of ISG. As shown previously, serum and CSF specimens from untreated healthy as well as infected animals did not kill strain K79. Table 2 summarizes the opsonic activity of sera from five different treatment groups. All animals receiving ISG alone died before therapy day 3 and sera were not available. An incubation of sera in the presence of penicillinase at 37" C for 1 h completely abolished the killing activity of sera from the penicillin group.
Nevertheless, almost all sera from the penicillin + ISG 2g/kg group (1 1/12 or 92%) exhibited efficient opsonic activity: >80% killing of the original inoculum was observed at 1 h of incubation.
In animals receiving penicillin G + ISG 1, 0.5, or 0.25 g/kg, most of the sera (60-70%) also supported >80% killing of the original inoculum.
Many previous investigators have suggested a beneficial therapeutic effect of combining human y globulin and antibiotics against infections caused by various gram-positive and gramnegative organisms (20) (21) (22) (23) . In addition, Shigeoka et al. (24) have shown that infants infected with GBS and transfused with whole blood containing specific opsonic antibody have improved survival when compared with infants receiving blood lacking antibody to the infecting strains. Because of the significant mortality and morbidity associated with neonatal GBS infections, more information is needed regarding combined chemotherapy and immunotherapy. The feasibility of this approach has been aided by the availability of ISG preparations modified for intravenous use because intravenous ISG preparations, compared with intramuscular ISG, produce immediate high blood levels of antibody and can be an advantageous adjunct. The availability of the newborn rat model of experimental GBS bacteremia and meningitis (25) has also been helpful. As shown previously (14, 16, 17, 25) , this model has several important similarities to GBS infections in human newborns: age dependency, hematogenous infection of the meninges without requiring mechanical disruption of the blood-brain barrier, and high mortality. In addition, techniques developed for serial atraumatic collection of blood and CSF specimens enable us to use this experimental model to evaluate treatment efficacies not only by mortality rates, but also be rates of bacterial clearance from blood and CSF.
Our findings revealed that ISG alone was not efficacious in the treatment of established GBS infection, in contrast to those of our previous studies which showed that ISG was extremely effective in providing protection in the same newborn rat model against oral or subcutaneous challenge of the same type I11 GBS strain (13, 26) . These findings are in agreement with those of other investigators (27, 28) who found that ISG did not protect newborn rats from lethal challenge with GBS when administration of ISG was delayed 12-15 h after bacterial inoculation. Also, in this study, penicillin G at the dose of 200 mg/kg/day alone failed to ensure the successful therapy of GBS infection: 18% (41 22) of the animals died and 38% (711 8) still had bacteremia after 1 day of penicillin therapy. This limited value of penicillin G was observed despite use of a highly penicillin-sensitive strain (minimal inhibitory and minimal bacteridical concentrations of 0.06 and 0.06 pg/ml) to induce bacteremia and meningitis and also achievement of excellent bactericidal titers in serum and CSF against the infecting strain after administering penicillin G. Recently, we have shown that rates of bacterial clearance and mortality do not differ significantly even with use of much higher doses of penicillin G (800 mg/kg/day) (29) . The reasons for this limitation of penicillin therapy are not clear; one possibility may be that in some animals, GBS infections may have been advanced too far and thus not readily controlled by penicillin therapy. For example, when we compared the pretherapy bacterial counts in blood between animals that died within 1 day of therapy or remained bacteremic at the end of 1 day of therapy with animals that survived and were free of bacteremia at the end of I day of therapy, the former group had significantly higher bacterial counts in blood than the latter group (6.43 +-0.60 versus 4.75 +-1.02 loglo CFU/ml, p < 0.001). Thus, the size of bacterial population at the beginning of therapy may have influenced the efficacy of penicillin therapy. Such an inoculum effect has also been well documented in vitro (30, 3 1).
When ISG was given to infected animals in conjunction with penicillin G, mortality rates did not differ significantly from those receiving penicillin G alone. However, the incidence of bacteremia at the end of 1 day of treatment was significantly lower, particularly in animals receiving penicillin G + ISG r 0.5 g/kg. The clinical significance of this finding is not clear. Since outcome from neonatal Escherichia coli meningitis has been shown to correlate directly with the duration of positive bacterial cultures in CSF (32, 33), it is conceivable that delayed bacterial eradication may contribute to the significant morbidity associated with neonatal GBS infection. In addition, sera from animals that received penicillin G + ISG exhibited efficient opsonophagocytic activity (>80% killing of the initial inoculum) even after the removal of penicillin-mediated killing activity. These findings support the salutary effect of passively administered ISG in restoring the opsonic activity of infected hosts against GBS which may further improve the efficacy of penicillin therapy against neonatal GBS disease. Additional studies are needed to deter-
